Your prescriber will assess both the therapeutic benefits and any troublesome side effects to ensure the medication remains appropriate for your individual circumstances
The dose schedule is a guideline, not a contract
The absolute risk increase for diabetic retinopathy complications was greater among patients with a history of diabetic retinopathy at baseline (semaglutide 8.2%, placebo 5.2%) than among patients without a known history of diabetic retinopathy (semaglutide 0.7%, placebo 0.4%)
Clinical trials report nausea in 25-40% of patients, with vomiting in 5-15%
A phase 2 clinical trial (NCT06092034) is currently underway to evaluate the safety and efficacy of RP-A501 in male participants aged 8 years and older
Vargas J, Junco M, Gomez C, Lajud N